Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

80%

4 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
4(80.0%)
Phase 2
1(20.0%)
5Total
Phase 3(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04182373Phase 3Completed

KW-3357 Study in Patients With Early Onset Severe Preeclampsia

Role: collaborator

NCT02184741Phase 3Completed

A Study of the Efficacy and Safety of GB-0998 in Patients With Unexplained Recurrent Miscarriage

Role: lead

NCT02032095Phase 2Completed

The Desensitization Therapy With GB-0998 for Anti-donor Antibody-positive Recipients.

Role: lead

NCT02342184Phase 3Completed

Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome

Role: lead

NCT00335985Phase 3Completed

Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM)

Role: lead

All 5 trials loaded